Evidence map›Paper›PMID 40381097›Full record

ArticleApplied biochemistry and biotechnology2025

miR-128-3p Reduces Proliferation and Immune Escape in Acute Myeloid Leukemia Through Targeted Regulation of ZEB1.

YanBin Zhang, DanDong Ma, XiaoJuan Zhang, WenKun Chen, XueJiao Wang, Rui Sun, KuiXing Li

Abstract read
PubMed Publisher
In one paragraph

Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. miR-330-3p Inhibits the Development of Acute Myeloid Leukemia by Targeting SYTL4.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

YanBin Zhang *Department of Hematology, Peking Union Medical College Hospital, No.1 Shuaifuyuan, Dongcheng District, Beijing City, 100730, China.
DanDong Ma *Department of Inspection Division, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang City, 441000, Hubei Province, China.
XiaoJuan ZhangDepartment of Hematology, Peking Union Medical College Hospital, No.1 Shuaifuyuan, Dongcheng District, Beijing City, 100730, China.
WenKun ChenDepartment of Hematology, Peking Union Medical College Hospital, No.1 Shuaifuyuan, Dongcheng District, Beijing City, 100730, China.
XueJiao WangDepartment of Hematology, Peking Union Medical College Hospital, No.1 Shuaifuyuan, Dongcheng District, Beijing City, 100730, China.
Rui SunDepartment of Hematology, Peking Union Medical College Hospital, No.1 Shuaifuyuan, Dongcheng District, Beijing City, 100730, China.
KuiXing LiDepartment of Hematology, Peking Union Medical College Hospital, No.1 Shuaifuyuan, Dongcheng District, Beijing City, 100730, China. Dr.likuixing@outlook.com.ORCID http://orcid.org/0009-0002-4274-8036

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

microRNAs have received wide attention as potential therapeutic targets. This study explored the action of miR-128-3p in acute myeloid leukemia (AML). miR-128-3p expression in AML was determined by quantitative PCR method. MTT proliferation assay and immunoblot assay were employed to detect proteins related to proliferation and apoptosis in THP-1 cells overexpressing miR-128-3p. RNA immunoprecipitation and dual luciferase reporting system were utilized to verify downstream targets of miR-128-3p. Flow cytometry was conducted to analyze the apoptosis rate and immune escape of THP-1 cells in the T-cell co-culture system. miR-128-3p was lowly expressed in AML patients (reduced by 41.6%). Overexpression of miR-128-3p inhibited THP-1 cell proliferation and immune escape, and stimulated apoptosis. ZEB1 was a downstream target of miR-128-3p, and up-regulation of miR-128-3p inhibited ZEB1 mRNA and protein expression (respectively reduced by 65.8% and 42.0%). Upregulating ZEB1 reversed the inhibitory effect of upregulating miR-128-3p on THP-1 cell proliferation and immune escape. Upregulating ZEB1 promoted PD-L1 protein expression (increased by 0.75-fold). Blocking PD-L1 reversed the promotion of THP-1 cell proliferation and immune escape by upregulating ZEB1. The miR-128-3p/ZEB1/PD-L1 axis is involved in regulating the proliferation and immune escape of AML cells, providing new insights into the molecular mechanism of miR-128-3p in AML and, more importantly, a new target for immunotherapy of AML.

Indexed as

Cell ProliferationGene Expression Regulation, LeukemicLeukemia, Myeloid, AcuteMicroRNAsRNA, NeoplasmTumor EscapeZinc Finger E-box-Binding Homeobox 1ApoptosisB7-H1 AntigenCell Line, TumorFemaleHumansMaleMiddle AgedTHP-1 CellsB7-H1 AntigenCD274 protein, humanMicroRNAsMIRN128 microRNA, humanRNA, NeoplasmZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1Acute myeloid leukemiamiR-128-3pPD-1PD-L1ZEB1

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.